Santisteban-Espejo, AntonioPerez-Requena, JoseAtienza-Cuevas, LidiaMoran-Sanchez, Juliadel Carmen Fernandez-Valle, MariaBernal-Florindo, IreneRomero-Garcia, RaquelGarcia-Rojo, Marcial2025-01-072025-01-072021-12-01https://hdl.handle.net/10668/25268The prognostic impact of the presence of Epstein-Barr virus (EBV) in classical Hodgkin lymphoma (cHL) is controversial. Previous studies reported heterogeneous results, rendering difficult the clinical validation of EBV as a prognostic biomarker in this lymphoma. The objective of this study was to evaluate the survival impact of the expression of EBV Latent-Membrane Protein 1 (EBV-LMP1) in tumoral Hodgkin-Reed-Sternberg (HRS) cells of primary diagnostic samples of cHL. Formalin-Fixed Paraffin-Embedded (FFPE) lymph node samples from 88 patients with cHL were analyzed. Patients were treated with the standard first-line chemotherapy (CT) with Adriamycin, Bleomycin, Vinblastine and Dacarbazine (ABVD) followed by radiotherapy. The Kaplan-Meier method and the Cox proportional hazards model were used for carrying out the survival analysis. In order to investigate whether the influence of EBV was age-dependent, analyses were performed both for patients of all ages and for age-stratified subgroups. In bivariate analysis, the expression of EBV was associated with older age (p = 0.011), mixed cellularity subtype cHL (penAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/B-cell lymphomasclassical Hodgkin lymphomaEpstein-Barr virusLatent-Membrane Protein 1risk-adjusted therapyAge-defined subgroupsReed-sternberg cellsB-cellsPresenting featuresDiseaseImpactEbvInfectionLmp1Membrane-protein-1research article34960792open access10.3390/v131225231999-4915https://www.mdpi.com/1999-4915/13/12/2523/pdf?version=1639711053737465700001